HK$4.89
1.11%
Hong Kong, Fri, Sep 18 2026.
ISIN
BMG210A71016
Symbol
512

Grand Pharmaceutical Target price 2026 - Analyst rating & recommendation

Grand Pharmaceutical Classifications & Recommendation

Buy
83%
Hold
17%

Grand Pharmaceutical Price Target

Target Price HK$8.46
Price HK$4.89
Potential
Number of Estimates 3
3 Analysts have issued a price target Grand Pharmaceutical 2027 . The average Grand Pharmaceutical target price is HK$8.46. This is higher than the current stock price. The highest price target is
HK$10.58 116.66%
register free of charge
, the lowest is .
A rating was issued by 6 analysts: 5 Analysts recommend Grand Pharmaceutical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Grand Pharmaceutical stock has an average upside potential 2027 of . Most analysts recommend the Grand Pharmaceutical stock at Purchase.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion HK$ 12.28 12.91
5.48% 5.07%
EBITDA Margin 18.63% 21.32%
20.34% 14.45%
Net Margin 10.10% 12.20%
52.34% 20.77%

4 Analysts have issued a sales forecast Grand Pharmaceutical 2026 . The average Grand Pharmaceutical sales estimate is

HK$12.9b
unlock
. This is
2.72% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
HK$14.2b 12.86%
unlock
, the lowest is
HK$11.4b 9.48%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 HK$12.3b 5.48%
2026
HK$12.9b 5.07%
unlock
2027
HK$14.0b 8.63%
unlock
2028
HK$16.0b 14.09%
unlock

3 Grand Pharmaceutical Analysts have issued a net profit forecast 2026. The average Grand Pharmaceutical net profit estimate is

HK$1.6b
unlock
. This is
38.87% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
HK$1.7b 45.99%
unlock
, the lowest is
HK$1.5b 33.23%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 HK$1.2b 49.73%
2026
HK$1.6b 26.84%
unlock
2027
HK$1.8b 13.48%
unlock
2028
HK$2.0b 13.86%
unlock

Net Margin

2025 10.10% 52.34%
2026
12.20% 20.77%
unlock
2027
12.74% 4.43%
unlock
2028
12.71% 0.24%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share HK$ 0.35 0.45
50.00% 28.57%
P/E 10.87
EV/Sales 1.66

3 Analysts have issued a Grand Pharmaceutical forecast for earnings per share. The average Grand Pharmaceutical EPS is

HK$0.45
unlock
. This is
40.63% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
HK$0.47 46.88%
unlock
, the lowest is
HK$0.43 34.38%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 HK$0.35 50.00%
2026
HK$0.45 28.57%
unlock
2027
HK$0.51 13.33%
unlock
2028
HK$0.58 13.73%
unlock

P/E ratio

Current 15.27 19.53%
2026
10.87 28.79%
unlock
2027
9.58 11.87%
unlock
2028
8.41 12.21%
unlock

Based on analysts' sales estimates for 2026, the Grand Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.70 40.56%
2026
1.66 2.63%
unlock
2027
1.52 7.95%
unlock
2028
1.34 12.35%
unlock

P/S ratio

Current 1.40 48.56%
2026
1.36 2.64%
unlock
2027
1.25 7.95%
unlock
2028
1.10 12.35%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today